Rangaswamy Govindarajan

Professor

UAMS primary UA Little Rock

Also affiliated: Louisiana State University (2006); University of Arkansas Medical Center (2012); Central Arkansas Veterans Healthcare System (2005–2017); Cancer Research Center (1997–2003); University of Kansas Medical Center (2009); Winthrop Rockefeller Foundation (2011–2015); Frederick National Laboratory for Cancer Research (1997); John L. McClellan Memorial Veterans Hospital (1997–2020); Louisiana State University Health Sciences Center New Orleans (2006); Science Applications International Corporation (United States) (1997)

Faculty Researcher

Internal Med, College of Medicine

14 h-index 68 pubs 1,533 cited

Research Areas

Biomedical Subjects

Links

Research Group UAMS TRI Profile

OverviewAI-generated summary

Rangaswamy Govindarajan investigates novel therapeutic strategies for various cancers, with a particular focus on gastrointestinal cancers, sarcoma, and melanoma. His work includes evaluating the efficacy of combination therapies and the impact of interventions on patient quality of life. He has published research on immune checkpoint blockade in rare tumors, such as desmoid tumors, and on enhancing immune responses in hepatocellular carcinoma using oncolytic viruses and checkpoint inhibitors.

Dr. Govindarajan's research also extends to managing treatment-related toxicities, including a study on preventing oxaliplatin-induced peripheral neuropathy. He is interested in the psychological well-being of patients with advanced cancer, exploring interventions like self-affirmation to improve their experience. His work contributes to understanding treatment outcomes and the multifaceted aspects of cancer care, from novel drug development to supportive interventions and quality of life assessments.

Research Overview

Dr. Rangaswamy Govindarajan is a hematologist and medical oncologist at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS) and the Central Arkansas Veterans Healthcare System (CAVHS). He is also a Professor in the UAMS Department of Internal Medicine, Division of Hematology/Oncology.Dr. Govindarajan received his medical degree from Mysore Medical College at the University of Mysore in Mysore, India. He completed an internship in General Medicine, Surgery and Ob/GYN/Pediatrics at K.R. Hospital & Cheluvamba Hospital in Mysore, India. Dr. Govindarajan completed his medical training at UAMS, first with a residency in Internal Medicine and then, as a fellow in the Division of Hematology/Oncology. He is board certified in Internal Medicine, Hematology and Oncology and is a Diplomate of the American Board of Internal Medicine.Dr. Govindarajan is a member of the American Society of Hematology and the American Society of Clinical Oncology. His primary clinical and research interests are gastrointestinal cancers, sarcoma and melanoma.

Metrics

h-index: 14
Publications: 68
Citations: 1,533

Selected Publications

Abstract 4378: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2026)

Cancer Research DOI OpenAlex
Alliance A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II Study (2026)

JCO oncology advances. 1 citation DOI OpenAlex
Quality-of-life outcomes in newly diagnosed advanced cancer: subgroup analysis – a case for individual differences (2026)

BMJ Supportive & Palliative Care DOI OpenAlex
A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence (2026)

medRxiv DOI OpenAlex
Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response (2026)

Journal for ImmunoTherapy of Cancer DOI OpenAlex
An alternative perspective on the Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being 12 item Scale (FACIT-Sp-12) in people newly diagnosed with advanced cancer (2025)

Journal of Psychosocial Oncology DOI OpenAlex
Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)

Frontiers in Immunology 1 citation DOI OpenAlex
Genetic counseling (GC) in the era of next generation sequencing (NGS) to diagnose microsatellite instability (MSI) and deficient mismatch repair (dMMR) expression in colorectal cancer (CRC). (2025)

Journal of Clinical Oncology DOI OpenAlex
Incidence and impact of incidental pulmonary embolism in solid cancer patients. (2025)

Journal of Clinical Oncology DOI OpenAlex
Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade (2024)

Molecular Therapy Oncology 5 citations DOI OpenAlex
Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors (2024)

Journal for ImmunoTherapy of Cancer 9 citations DOI OpenAlex
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27). (2023)

Journal of Clinical Oncology DOI OpenAlex
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial (2020)

Nature Medicine 115 citations DOI OpenAlex
Survival Outcomes in Stage IV Bladder Cancer Patients Treated with Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine: A Retrospective Analysis in Veteran Patients (2020)

Clinical Oncology and Research DOI OpenAlex
C-reactive protein (CRP) as a predictive biomarker in lung cancer patients receiving immune checkpoint inhibitors (ICI). (2020)

Journal of Clinical Oncology 4 citations DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

As listed on this researcher's institutional profile.

CALGB 30610 Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etopos NIH/Nat. Cancer Institute via Cancer and Leukemia Group B Principal Investigator
A Randomized, Open Label Multi-Center Study of XRP6258 At 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared To Mitoxantrone in Combinatio Sanofi-Aventis Principal Investigator
CTSU ECOG 2108, A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cance NIH/Nat. Cancer Institute via Eastern Cooperative Oncology Group Principal Investigator
UARK 2004-40: A Companion Protocol for Biomarker Development and Pharmacogenetic Analysis in Subjects Enrolled in Clinical Therapeutic Trials Using Pa Amgen, Inc. Principal Investigator
A Pivotal Trial to Determine the Efficacy and Safety of AP23573 When Administered as Maintenance Therapy to Patients with Metastatic Soft Tissue or Bo Merck & Company, Inc. Principal Investigator
RANDOMIZED PHASE III TRIAL COMPARING EVEROLIMUS PLUS PLACEBO VERSUS EVEROLIMUS PLUS BEVACIZUMAB FOR ADVANCED RENAL CELL CARCINOMA PROGRESSING AFTER TR NIH/Nat. Cancer Institute via Cancer and Leukemia Group B Principal Investigator
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer (CALGB 80803) NIH/Nat. Cancer Institute via Cancer and Leukemia Group B Principal Investigator
CALGB 30801 A RANDOMIZED PHASE III DOUBLE BLIND TRIAL EVALUATING SELECTIVE COX-2 INHIBITION IN COX-2 EXPRESSING ADVANCED NON-SMALL CELL LUNG CANCER NIH/Nat. Cancer Institute via Cancer and Leukemia Group B Principal Investigator

A Phase III multicenter, international, randomized, double-blind, placebo-controlled study of doxorubicin plus palifosfamide-tris vs. doxorubicin plus Ziopharm, Inc. Principal Investigator
CTSU ACOSOG Z6051 A Phase III Prospective Randomized Trial Comparing Laparoscopic-assisted Resuction Versus Open Resection for Rectal Cancer CFDA 93.3 NIH/Nat. Cancer Institute Principal Investigator
Genetic Analysis to Evaluate the Racial Difference in the Outcome of Patients with Colon Cancer Genomic Health Principal Investigator
A Phase 1/2 Study of Aflibercept Administered in Combination with Pemetrexed and Cisplatin in Patients with Advanced Carcinoma Regeneron Pharmaceuticals Principal Investigator
A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated Janssen Research & Development, LLC Principal Investigator
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial QED Therapeutics, Inc. Principal Investigator
CTSU CALGB E1208 A Phase III Randomized, Double-Blind Trial of Chemoembolization NIH/Nat. Cancer Institute via Cancer Trials Support Unit Principal Investigator
CTSU CALGB 90601 A Randomized Doble-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab (IND #7921, NSC #704865) to Gemcitabine, NIH/Nat. Cancer Institute via Cancer Trials Support Unit Principal Investigator
UARK 2004-44 (CGI G-0029): A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients with Metastatic H Cell Genesys, Inc Principal Investigator
UARK 2004-35: A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Whose Tumors Expres Amgen, Inc. Principal Investigator
S2303, Randomized Phase II/III Trial of Second-Line Nivolumab Plus Paclitaxel and Ramucirumab Versus Paclitaxel and Ramucirumab in Patients With PD-L1 CPS =1 Advanced Gastric or Esophageal Adenocarcinoma (PARAMUNE) NIH/Nat. Cancer Institute Principal Investigator
A PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER (273375) Alliance for Clinical Trials in Oncology Principal Investigator
CTSU N0949 Randomized Phase III Trial of mFOLFOX7 or XELOX Plus Bevacizumab versus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First NIH/Nat. Cancer Institute via Cancer Trials Support Unit Principal Investigator
S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers (IRB 239746) NIH/Nat. Cancer Institute via SouthWest Oncology Group Principal Investigator
A Multiple-Dose, Non-Randomized, Open-Label, Multicenter Study to Evaluate the Long-Term Safety and Effectiveness of EN3267 in the Treatment of Breakt Endo Pharmaceuticals Principal Investigator
UARK 2002-17 A Phase II, Randomized, Open-Label, Controlled, Dose-Evaluation, Multicenter Trial of Thalidomide for the Prevention of Diarrhea Associat Upjohn, Inc. Principal Investigator
Global Investigation of Therapeutic Decisions in Hepatocellular carcinoma and Of itsTreatment with SorafeNib Baxter Healthcare Corporation Principal Investigator
CTSU N0923 A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreducti NIH/Nat. Cancer Institute via Cancer Trials Support Unit Principal Investigator
UARK 2004-36 (20030167): A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer followin Amgen, Inc. Principal Investigator
ECOG 1609 A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy NIH/Nat. Cancer Institute via Eastern Cooperative Oncology Group Principal Investigator